Shattuck Labs (STTK) Accumulated Expenses (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Accumulated Expenses of $3.0 million for Q1 2026, down 48.18% year-over-year from $5.8 million in Q1 2025, and down 39.49% quarter-over-quarter from $5.0 million in Q4 2025.
Shattuck Labs (STTK) Accumulated Expenses (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Accumulated Expenses for 8 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 48.18% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (down 48.18% YoY), while the FY2025 annual figure was $5.0 million, down 23.81% from the prior year.
- Accumulated Expenses eased to $3.0 million in Q1 2026 per STTK's latest filing, from $5.0 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $18.6 million in Q2 2022 and bottomed at $3.0 million in Q1 2026.
- Historically, Accumulated Expenses has averaged $9.5 million across 5 years, with a median of $9.5 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses surged 170.93% — and 2025, when it slumped 55.94%.
- Shattuck Labs' Accumulated Expenses stood at $17.8 million in 2022, then slumped by 44.56% to $9.9 million in 2023, then plunged by 34.14% to $6.5 million in 2024, then retreated by 23.81% to $5.0 million in 2025, then slumped by 39.49% to $3.0 million in 2026.
- Business Quant data shows STTK's Accumulated Expenses at $3.0 million in Q1 2026, $5.0 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.79 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 4.95 Mn |
| Sep 30, 2025 | 4.17 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 5.78 Mn |
| Dec 31, 2024 | 6.50 Mn |
| Sep 30, 2024 | 9.47 Mn |
| Jun 30, 2024 | 6.50 Mn |
| Mar 31, 2024 | 7.57 Mn |
| Dec 31, 2023 | 9.87 Mn |
| Sep 30, 2023 | 12.04 Mn |
| Jun 30, 2023 | 9.52 Mn |
| Mar 31, 2023 | 10.88 Mn |
| Dec 31, 2022 | 17.80 Mn |
| Sep 30, 2022 | 16.10 Mn |
| Jun 30, 2022 | 18.57 Mn |
| Mar 31, 2022 | 14.22 Mn |
| Dec 31, 2021 | 14.57 Mn |
| Sep 30, 2021 | 13.78 Mn |